A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Metabolic disorders
- Focus Therapeutic Use
- Acronyms SIRONA
- Sponsors Longeveron
- 31 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 31 Dec 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2020.
- 31 Dec 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2019.